CKS1B

Across TCGA pan-cancer cohorts, CKS1B mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of CKS1B’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where CKS1B mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types CKS1B is over-expressed in tumor.

CCRCC, HNSC, and LSCC are the cancer types where CKS1B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CKS1B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	III,IV	+1.137	<.001	12	view →
HNSC	All	IV	+0.829	<.001	11	view →
LSCC	Male	II,III,IV	+1.285	<.001	9	view →
LUAD	Male	All	+0.936	<.001	9	view →
PDAC	Female	All	+0.867	<.001	6	view →
COAD	All	All	+0.599	.005	4	view →
OV	All	All	+1.223	.018	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

CKS1B–CCRCC

Open the CCRCC breakdown →